CompanyMPLTNasdaqRedwood City, CA

MapLight Therapeutics

MapLight Therapeutics develops circuit-specific pharmacotherapies for central nervous system disorders.

SEC EDGAR ClinicalTrials.gov maplightrx.com

424B3Sep 23Latest SEC filing

Sep 9Latest story

September 2026

MapLight Therapeutics registers 13.2 million shares for resale after $150 million private placement

Sep 9FinancingMapLight Therapeutics

August 2026

MapLight enters $150M private placement agreement, reports Q2 2026 results

Aug 13Clinical readoutMapLight Therapeutics ML-007C-MA

July 2026

MapLight's ML-007C-MA hits primary endpoint, company plans confirmatory pivotal trial

Jul 27Clinical readoutMapLight Therapeutics ML-007C-MA